AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01515592 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Liraglutide placebo administered to subjects randomised at each dose level in the ratio of 3:1
Study NCT03414450 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ETC-1907206
Description: ETC-1907206 gelatin capsules will be dosed every other day (EOD) and contain 10 mg or 50 mg of ETC-1907206.
Study NCT03414450 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dasatinib
Description: dasatinib tablets at 140 mg will be dosed every day
Study NCT03057210 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stress Protocol
Description: Participants will be submitted to an exercise protocol consisting of a jumping program and a maximum short cycle test (ALMEIDAetal). The jumping program consists of 10 sets of 10 jumps with one minute interval between sets. The participants will then perform the Wingate Anaerobic Test protocol, which will be performed on a Biotec 2100 cycle ergometer (Cefise, Nova Odessa, Brazil). A 5-minute warm-up will be carried out where the participant will pedal at a speed of 60 to 90 rpm with a fixed load of 1.0 kg and perform sprints in the 2nd and 4th minute and the test itself, which consists of a maximum of pedals In 30 seconds with a stipulated load of 0.075 kP · kg-1 of the participant's body mass.
Study NCT03057210 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Massage Protocol
Description: the present protocol will have a total of 12 minutes duration, being six minutes in the anterior region of the thigh (three minutes for each limb) and six minutes in the posterior region of the trunk.~Surface and deep sliding techniques will be used, the latter being presented in two intensities, moderate or intense, gradually increased. The massage will be performed towards the muscle fibers, from distal to proximal and following the lymphatic flow. In addition to the standardization of the intensity of the massage performed by the physiotherapist, in order to avoid causing discomfort and possible variations in the application of the technique, participants should report their level of comfort from a scale that considers the technique light, moderate or Intense, corresponding respectively to surface slip, Deep Slip 1 and Deep Slip 2.
Study NCT04342650 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chloroquine Diphosphate
Description: 150mg tablets Note: Tablets used in the study were Chloroquine Diphosphate (produced by Farmanguinhos/Fiocruz), and the dosing stated in the clinicaltrials.gov refers to chloroquine base (in mg).
Study NCT04342650 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: 150mg placebo tablets
Study NCT01868945 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 5 µg/day Hy.D Calcifediol
Description: 5 µg/day Hy.D Calcifediol taken together with breakfast for a total period of 24 weeks
Study NCT01868945 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 10 µg/day Hy.D Calcifediol
Description: 10 µg/day Hy.D Calcifediol taken together with breakfast for a total period of 24 weeks
Study NCT01868945 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 15 µg/day Hy.D Calcifediol
Description: 15 µg/day Hy.D Calcifediol taken together with breakfast for a total period of 24 weeks
Study NCT01868945 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: 20 µg/day vitamin D3
Description: 20 µg/day vitamin D3 taken together with breakfast for a total period of 24 weeks
Study NCT03075761 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fitbit
Description: The Fitbit will be utilized in the intervention arm to improve adherence to a 12-week activity regimen.
Study NCT03075761 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: 30-minute education session
Study NCT03075761 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 30-minute education session
Study NCT01506076 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levocetirizine DiHCl
Description: Levocetirizine DiHCl Tablets 5 mg
Study NCT01506076 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levocetirizine DiHCl
Description: Levocetirizine DiHCl Tablets 5 mg
Study NCT04575324 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telemedicine Linkage Intervention
Description: Participants will be immediately linked to telemedicine care provided by an FQHC provider waivered to prescribe buprenorphine and naltrexone or able to refer patients to methadone treatment. Participants will have their vitals checked and be virtually connected to the provider. The research assistant will share the vitals with the provider, and the provider will provide personalized care during which they discuss treatment options with the participant. If a medication for opioid use disorder is prescribed or if a methadone referral is made, transportation assistance will be provided to the participant as part of the intervention. Transportation to pick up the prescription or complete the first appointment will be provided via a HIPAA compliant ride-share company, and a bus pass will be provided to the participant for the return trip.
Study NCT00580099 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: assisted exercise
Description: 4 weeks of passive range of motion exercise
Study NCT00580099 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: cuddle
Description: cuddle infant for 20 minutes
Study NCT00142753 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Engerix B
Description: Standard adult dose for A1; increased adult dose for A2. Doses at Entry, Weeks 4 and 24. Non-responders (\<10 IU/mL of antibody at week 28/4 weeks after dose #3) will receive Engerix-B increased adult dose at Week 48.
Study NCT00142753 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Engerix B
Description: Standard adult dose for A1; increased adult dose for A2. Doses at Entry, Weeks 4 and 24. Non-responders (\<10 IU/mL of antibody at week 28/4 weeks after dose #3) will receive Engerix-B increased adult dose at Week 48.
Study NCT00142753 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Twinrix for ATN 024
Description: Standard adult dosage, taken at Entry, Weeks 4 and 24. Non-responders (\<10 IU/mL of antibody at week 28/4 weeks after dose #3) will receive Engerix-B increased adult dose at week 48.
Study NCT00142753 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombivax
Description: Dosage at entry and week 24; non-responders ((\<10 IU/mL of antibody at week 28/4 weeks after dose #3) will receive 3rd dose of Recombivax during weeks 48-72.
Study NCT00142753 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Twinrix for ATN 025
Description: Doses at Entry and Week 24. Non-responders (\<10 IU/mL of antibody at week 28/4 weeks after dose #3) will receive a dose of Recombivax during week 48-72.
Study NCT03173963 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Empagliflozin
Description: 10 mg tablet of empagliflozin daily in addition to best clinical practice for management of diabetes.
Study NCT03173963 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1placebo tablet per day
Study NCT00818844 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nepafenac 0.1%
Description: NSAID
Study NCT00818844 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: BSS
Description: BSS
Study NCT02584296 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BSMA
Description: Biobehavioral self-management approach (BSMA) intervention is aligned with information-motivation-behavioral skills (IMB) model and is guided physical activity (PA). Collects demographic, medical, disease, treatment data, blood specimens and the battery of measures. Includes PA self-assessment, 6 minute walk test(6MWT) and chair squat test (CST) with Physical Therapist (PT); provides PA handouts based on American Cancer Society (ACS) guidelines, discusses known benefits, beliefs and goals of PA (IMB health behavior motivation); assess/discuss perceived barriers to PA. PT or Exercise physiologist (EP) works with subject on various exercises (both strength and aerobic, \~30 minutes; IMB behavioral skills);PT or EP reviews exercises, subject practices, and provides a BSMA program (including strength/aerobic training) for subject to begin upon discharge. Subject keeps journal of PA and wears accelerometer (TAA) to record PA levels. 3-weeks at home study nurse calls subjects each week.
Study NCT00915525 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: botulinum toxin Type A
Description: Botulinum toxin Type A 100U or 150U injected into the detrusor, after protocol specified criteria are met, and no more frequently than every 12 weeks.
Study NCT02487121 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: variable interval schedule
Description: 12 group-based extended care treatment sessions scheduled in 3, 4-week periods over a 12-month period
Study NCT02487121 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: self-directed treatment
Description: provision of treatment materials with instruction to work through materials at participant's own pace
Study NCT01433913 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metformin hydrochloride
Description: Given PO
Study NCT01433913 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Given PO
Study NCT01433913 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT04205552 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Relatlimab 10 MG/ML Intravenous Solution
Description: Neoadjuvant 2 cycles, every two weeks (q2w) Relatlimab 80 mg i.v. over 30 min
Study NCT01433913 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT02847767 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Perfusion Imaging
Description: IV contrast perfusion CT will be performed at baseline and at 1 week after completing treatment. Perfusion imaging is similar to a diagnostic CT except a smaller region is serially imaged post contrast injection with multiple data acquisitions and high temporal resolution
Study NCT02582632 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ombitasvir/paritaprevir/ritonavir
Description: Tablet
Study NCT02582632 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dasabuvir
Description: Tablet
Study NCT03298061 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mepolizumab
Description: Mepolizumab will be available as lyophilized powder for injection to be reconstituted with sterile water for injection, prior to use. Subjects will be dosed with mepolizumab at a dose of 300 mg which will be administered as three separate 100 mg SC injections every 4 weeks. The injections will be administered into any of the upper arm, thigh or anterior abdominal wall.
Study NCT03298061 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone
Description: Subjects who require a dose of prednisolone (or equivalent) of 5 mg/day for adequate control of their EGPA will be included.
Study NCT00597675 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Peanut OIT
Description: Defatted peanut flour ingested daily as oral mucosal immunotherapy
Study NCT00597675 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oat flour matched by weight and consistency that is ingested daily as a placebo
Study NCT01590615 — intervention group
Intervention type: DRUG
Intervention: Anti-HBV nucleoside/nucleotide therapy
Description: Subjects with chronic HBV infection and with decompensated liver disease who are receiving or anticipated to receive anti-HBV nucleoside/nucleotide therapy will be identified at centers with liver disease expertise where subjects are monitored on a regular basis.
Study NCT00440024 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tazorac
Description: Tazarotene 0.1% cream applied to the face once daily before bed
Study NCT00440024 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tazorac
Description: Tazarotene 0.1% cream applied to the face once daily before bed
Study NCT00440024 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dove Mild Cleanser
Description: Ultra mild cleanser: Dove Non-foaming cleansing lotion
Study NCT00440024 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dove Mild Cleanser
Description: Ultra mild cleanser: Dove Non-foaming cleansing lotion
Study NCT00440024 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dove Facial Moisturizer
Description: Moisturizing cream - Dove facial moisturizer with SPF 15
Study NCT00440024 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dove Facial Moisturizer
Description: Moisturizing cream - Dove facial moisturizer with SPF 15
Study NCT04302285 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PKU type meal and Exercise
Description: * Exercise was conducted prior to PKU type meal.~* PKU type meal was based on PKU special low protein foods (50% of total energy intake), natural free protein foods (37%) and protein substitute (13%). Calories provided in breakfast were 600 kcal and were not based on individual dietary requirement. 65% of total energy intake was provided from carbohydrate, 13% from protein and 22% from fat.
Study NCT04302285 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PKU type meal
Description: PKU type meal was based on PKU special low protein foods (50% of total energy intake), natural free protein foods (37%) and protein substitute (13%). Calories provided in breakfast were 600 kcal and were not based on individual dietary requirement. 65% of total energy intake was provided from carbohydrate, 13% from protein and 22% from fat.
Study NCT00266812 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide and radiotherapy
Description: Oral temozolomide 75mg/m2/day for 14 days, during radiation treatment, and later on temozolomide 100 mg/m2/day at 14 days on/14 days off, until unacceptable toxicity or evidence of disease progression for up to 6 cycles from initial treatment. Radiotherapy (as in Intervention 2).
Study NCT00266812 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Whole brain radiotherapy
Description: 2 regimens are allowed: a) 20 fractions of 2 Gray each, administered on days 1 to 5, 8 to 12, 15 to 19, and 22 to 26; b) 10 fractions of 3 Gray each, administered on days 1 to 5 and 8 to 12.
Study NCT02786667 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rotigotine
Description: 6 months treatment with Rotigotine up to 8 mg per day with a titration period for one month
Study NCT02786667 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 6 months treatment with Placebo up to 8 mg per day with a titration period for one month
Study NCT03142100 — intervention group
Intervention type: DEVICE
Intervention: cochlear implants and hearing aids
Description: speech perception tests and bimodal fitting
Study NCT02506036 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Brain HQ
Description: Brain HQ is a web application that will be used to provide patients with a training intervention that addresses deficits in social-emotional functions. These include areas such as identifying facial expression, understanding tone of voice, and predicting how people may react in certain situations. The training will take about 30 hours over the course of 4-6 weeks and is done at home.
Study NCT02506036 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Brain HQ
Description: Brain HQ is a web application that will be used to provide patients with a training intervention that addresses deficits in social-emotional functions. These include areas such as identifying facial expression, understanding tone of voice, and predicting how people may react in certain situations. The training will take about 30 hours over the course of 4-6 weeks and is done at home.
Study NCT01719302 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: 1500 mg/m\^2 given days 1 and 15 of every 28 day cycle for a total of 4 cycles
Study NCT01719302 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: 50 mg/m\^2 on days 1 and 15 of each 28 day cycle for a total of 4 cycles
Study NCT01719302 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pazopanib
Description: Starting dose of 400 mg/day starting 72 hours after docetaxel/gemcitabine administration for 10 days (days 4-13 and 18-27) of each 28 day cycle for a total of 4 cycles. Dose will be increased by 200 mg/day for each cohort until the maximum tolerated dose is identified.
Study NCT03427281 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: questionnaire
Description: questionnaire to assess the patterns of postoperative bracing use by spinal surgeons in Belgium
Study NCT00005585 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV
Study NCT00005585 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: Deoxycytidine analogue which is metabolized to ARA-CTP, a substance which inhibits DNA polymerase.
Study NCT00005585 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: daunorubicin hydrochloride
Description: Given IV
Study NCT00005585 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: Dexamethasone is a synthetic fluorinated glucocorticoid devoid of mineralocorticoid effects.
Study NCT00005585 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin calcium
Description: Synthetic d,l-5 CHO tetrahydrofolate, which is used to bypass the inhibition of dihydrofolate reductase by Methotrexate (MTX)
Study NCT00561353 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC435
Description: TMC435 25 mg, 75 mg, 150 mg, or 200 mg capsules taken orally (by mouth) once daily for 21 or 28 days.
Study NCT00005585 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mercaptopurine
Description: An analogue of the nucleic acid constituent adenine and the physiological purine base hypoxanthine
Study NCT00005585 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Description: A folate analogue which inhibits the enzyme dihydrofolate reductase, haltin g DNA, RNA, and protein synthesis
Study NCT00005585 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pegaspargase
Description: E-Coli asparaginase deaminates asparagine, thus, is lethal for cells which cannot synthesize asparagine.
Study NCT00005585 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: thioguanine
Description: Given orally
Study NCT00005585 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate
Description: Given IV
Study NCT02716285 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ileocolonic release peppermint oil
Description: Peppermint oil, menthae piperitae aetheroleum
Study NCT00561353 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules identical in appearance to TMC435 capsules taken orally (by mouth) once daily for 28 days.
Study NCT00561353 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Peginterferon (PegIFNα-2a)
Description: One subcutaneous (under the skin) injection containing 0.5 mL solution with 180 mcg PegIFNα-2a on Days 1, 8, 15, and 22
Study NCT00561353 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon (PegIFNα-2a)
Description: One subcutaneous (under the skin) injection containing 0.5 mL solution with 180 mcg PegIFNα-2a on Days 1, 8, 15, and 22
Study NCT03942445 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Gastrocnemius muscle biopsy
Description: In all groups, a 5 mm large gastrocnemius muscle biopsy will be performed and the samples immediately managed in experimental laboratory.
Study NCT02716285 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsule, containing microcrystalline cellulose
Study NCT02716285 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Small intestinal release peppermint oil
Description: Peppermint oil, menthae piperitae aetheroleum
Study NCT01051804 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Systane Ultra
Description: Systane Ultra 1 to 2 drops per eye at least 4 times daily for 4 weeks
Study NCT01051804 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Optive lubricant Eye Drops
Description: Optive Lubricant Eye Drops 1 to 2 drops per eye at least 4 times daily for 4 weeks
Study NCT04215770 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: inj co-amoxiclav 50 units/kg/day vs inj Benzyl Penicillin 25000 units/kg/day
Description: Patients of both groups were examined and compared in terms of efficacy of treatment, safety and cost effectiveness
Study NCT02328729 — intervention group
Intervention type: PROCEDURE
Intervention: mandibular block with Epinephrine
Description: Delivery of mandibular block anesthesia for dental treatment with Lidocaine HCl 2% with 1:100,000 Epineprine
Study NCT02328729 — intervention group
Intervention type: PROCEDURE
Intervention: C-CLAD-IL with Epinephrine
Description: Delivery of C-CLAD-ILanesthesia for dental treatment with Lidocaine HCl 2% with 1:100,000 Epineprine
Study NCT02328729 — intervention group
Intervention type: PROCEDURE
Intervention: Infiltration with Epinephrine
Description: Delivery of infiltration anesthesia for dental treatment with Lidocaine HCl 2% with 1:100,000 Epineprine